decisionhealth Newsletters, Coder Pink Sheets - 2009 Issue 6 (June)
MultiSpecialty RoundUp: Urology
Subscribe or sign in to view the full article.
Article Overview
This article is a short urology coding update focused on diagnosis coding considerations tied to Zometa use and a Medicare national coverage determination affecting PSA testing. It is intended for coding and reimbursement professionals who need to stay current on diagnosis code selection, coverage updates, and payer-facing guidance in urology. The piece references ICD-9-CM, HCPCS Level II, and Medicare policy context without providing a full technical deep dive.
Why This Topic Matters
The article highlights payer-sensitive coding issues that can affect reimbursement and documentation accuracy in urology. It is useful for coders and billers who need to recognize when diagnosis coding, medication use, and Medicare coverage policy intersect.
What You Will Learn
- How the article frames coding considerations related to Zometa use in urology
- What general Medicare coverage update is discussed for PSA testing
- Which broader diagnosis-code categories and payer guidance themes are mentioned in the update
- Why urology coders are advised to pay attention to diagnosis sequencing and coverage policy changes
Who Should Read This
- Urology coders
- Medical billers
- Reimbursement specialists
- Practice managers
- Compliance staff
Codes Discussed
Code Ranges Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com